Hiddo J.L. Heerspink

Featured in: Favicon

medscape.com Favicon

ahajournals.org Favicon

acpjournals.org Favicon

healio.com Favicon

diabetesjournals.org Favicon

asn-online.org Favicon

diabetesresearchclinicalpractice.com Favicon

onlinelibrary.wiley.com + 1 more

Articles

Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

Nov 12, 2023 | ahajournals.org | Brendon L Neuen |Hiddo J.L. Heerspink |Priya Vart |Brian Claggett

Background: Sodium glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone all individually reduce cardiovascular, kidney and mortality outcomes in patients with type 2 diabetes and albuminuria. However, the lifetime benefits of combination therapy with these medicines are not known.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →